Prior authorization (PA) is the process by which an insurer reviews whether a medication meets their coverage criteria before agreeing to pay. For GLP-1 weight loss medications, PA is nearly universal — and the denial rate is the single biggest barrier to access for insured patients.
Why PA denial rates are so high
GLP-1 medications for weight management are expensive — $1,000-1,300/month at list price. Insurers use prior authorization to manage utilization and costs. The PA criteria typically require documentation of BMI threshold (≥30, or ≥27 with comorbidities), prior failed weight loss attempts (diet, exercise, sometimes another medication), specific comorbidities, and prescribing by a qualified provider.
The criteria themselves are not unreasonable — they broadly track FDA label indications. The problem is implementation: automated PA systems often deny claims that technically meet criteria due to documentation formatting, missing codes, or criteria interpretation differences between the prescriber and the insurer's review algorithm.
Approval rates by insurer category
| Insurer Category | Initial Approval | After Appeal | Notes |
|---|---|---|---|
| Large employer commercial | 50-70% | 65-80% | Varies by whether plan explicitly covers AOMs |
| Small employer commercial | 30-50% | 45-65% | Many small plans exclude weight loss drugs |
| ACA marketplace | 40-60% | 55-70% | State mandates increasing coverage |
| Medicare Part D | 60-75% | 75-85% | Post-IRA coverage expansion (Wegovy for CVD risk) |
| Medicaid (state-dependent) | 20-50% | 35-60% | 13 states explicitly cover; others case-by-case |
Ranges reflect published survey data and industry estimates as of mid-2026. Individual insurer rates vary significantly within each category.
The appeal success rate
Appeals succeed 40-65% of the time when the initial denial is contested with complete documentation. This means a significant proportion of initial denials are administrative rather than clinical — the patient qualifies, but the first submission didn't include the right documentation in the right format.
The AMA's 2024 survey found that physicians spend an average of 14 hours per week on prior authorization activities across all medications. For anti-obesity medications specifically, the documentation burden per PA request is among the highest in outpatient medicine.
Initial PA denials are not final. Appeals with complete documentation succeed 40-65% of the time. The most common reasons for initial denial — insufficient documentation, missing prior weight loss attempt records, coding errors — are correctable. Patients who receive an initial denial should always appeal.
Workarounds patients use
Cash-pay programs. LillyDirect ($299-$449 for Zepbound vials), Wegovy savings programs ($349-$249/mo), and manufacturer copay cards bypass PA entirely for patients willing to pay out of pocket.
Compounding pharmacies. Compounded semaglutide and tirzepatide don't require prior authorization because they're not covered by insurance. This is the primary access pathway for patients whose insurance denies coverage or doesn't cover weight loss medications at all.
Indication-based prescribing. Some physicians prescribe GLP-1 agonists under the Type 2 diabetes indication (where PA approval rates are higher and more plans provide coverage) for patients who have both obesity and diabetes or pre-diabetes. This is clinically appropriate when both indications exist — it's label prescribing, not off-label.
State mandate advocacy. A growing number of states are mandating that commercial insurers cover FDA-approved anti-obesity medications. As of mid-2026, legislative activity in this area is increasing, with several states having passed or pending mandates that will improve access for residents of those states.